Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

EP300 Suppresses Leukemia Development in Myelodysplastic Syndrome through Myb Repression

Na Man, Gloria Mas Martin, PhD, Daniel Karl, PhD, Jun Sun, PhD, Fan Liu, PhD, Miguel Torres-Martin, PhD, Hidehiro Itonaga, MD PhD, Concepcion Martinez, B.S., Shi Chen, Stephanie Duffort, Pierre-Jacques Hamard, PhD, Ye Xu, PhD, Luisa Cimmino, PhDBSc, Feng-Chun Yang, MD PhD, Philip A. Cole, MD PhD, Mingjiang Xu, MD PhD, Maria E. Figueroa, MD, Stephen Nimer, MD

Blood (2019) 134 (Supplement_1): 561.

https://doi.org/10.1182/blood-2019-130507

Published: 2019

Journal Articles

CARM1/PRMT4 As a Novel Therapeutic Target for AML

Sarah Greenblatt, PhD, Na Man, Pierre-Jacques Hamard, PhD, Concepcion Martinez, B.S., Ye Xu, PhD, Fan Liu, PhD, Justin M Watts, MD, Daniel G. Tenen, MD, Stephen D. Nimer, MD

Blood (2017) 130 (Supplement 1): 241.

https://doi.org/10.1182/blood.V130.Suppl_1.241.241

Published: 2017

Journal Articles

TAFII250 Is Critical in AML1-ETO Mediated Leukemogenesis

Ye Xu, PhD, Na Man, PhD, Concepcion Martinez, Camilo Martinez, Felipe Beckedorf, Guoyan Cheng, PhD, Sarah Merin Greenblatt, PhD, Lan Wang, PhD, Ramin Shiekhattar, Stephen D. Nimer, MD

Blood (2016) 128 (22): 1520.

https://doi.org/10.1182/blood.V128.22.1520.1520

Published: 2016

Journal Articles

A Study on the Molecular Mechanism for Hereditary Type II Antithrombin Deficiency in a Chinese Pedigree.

Ye Xu, Ying Feng, Ying Pang, Peipei Jing, Xie Wei, Xuhong Zhou, Qiulan Ding, Xuefeng Wang

Blood (2006) 108 (11): 4006.

https://doi.org/10.1182/blood.V108.11.4006.4006

Published: 2006

Journal Articles

A Novel Heterozygous Point Mutation Causing Coagulation Factor XII Deficiency as the Molecular Mechanism of Fatal Thrombosis Event in a Chinese Pedigree.

Ying Feng, MD, Ye Xu, MD, Ying Pang, MD, Jing Dai, MD, Wei Xie, MD, Xuhong Zhou, MD, Qiulan Ding, MD, Xuefeng Wang, MD

Blood (2006) 108 (11): 4080.

https://doi.org/10.1182/blood.V108.11.4080.4080

Published: 2006

NARROW

EP300 Suppresses Leukemia Development in Myelodysplastic Syndrome through Myb Repression

CARM1/PRMT4 As a Novel Therapeutic Target for AML

TAFII250 Is Critical in AML1-ETO Mediated Leukemogenesis

A Study on the Molecular Mechanism for Hereditary Type II Antithrombin Deficiency in a Chinese Pedigree.

A Novel Heterozygous Point Mutation Causing Coagulation Factor XII Deficiency as the Molecular Mechanism of Fatal Thrombosis Event in a Chinese Pedigree.

Email alerts

ASH Publications

American Society of Hematology

EP300 Suppresses Leukemia Development in Myelodysplastic Syndrome through Myb Repression

CARM1/PRMT4 As a Novel Therapeutic Target for AML

TAFII250 Is Critical in AML1-ETO Mediated Leukemogenesis

A Study on the Molecular Mechanism for Hereditary Type II Antithrombin Deficiency in a Chinese Pedigree.

A Novel Heterozygous Point Mutation Causing Coagulation Factor XII Deficiency as the Molecular Mechanism of Fatal Thrombosis Event in a Chinese Pedigree.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only